A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer

Clinical Breast Cancer

Volumn 8, Issue 3, 2008, Pages 242-248

  Yardley, Denise A ^a   Burris III, Howard A ^a   Farley, Cindy P ^a   Barton, John H ^a   Peacock, Nancy W ^a   Spigel, David R ^a   Greco, F Anthony ^a   Hainsworth, John D ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Arthralgia; Dexamethasone; Dose reduction; Myalgia; Pegfilgrastim

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLEEDING; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; LACRIMATION DISORDER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; ONYCHOLYSIS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; THROMBOCYTOPENIA;

EID: 46949089116     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.027     Document Type: Article

References (22)

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352:930-42.
2. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-83.
3. Mamounas ER Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for nodepositive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23:3686-96.
4. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302-13.
5. Sparano JA, Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: results of Intergroup trial E1199. J Clin Oncol 2007; 25(18 suppl):65s (Abstract 516).
6. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C974/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003; 21:1431-9.
7. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23:5542-51.
8. Miller KD, McCaskill-Stevens W, Sisk J, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999; 17:3033-7.
9. DiLeo A, Crown J, Nogaret JM, et al. A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer. Ann Oncol 2000; 11:169-75.
10. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619-29.
11. Gebski V, Lagleva M, Keech A. Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. J Natl Cancer Inst 2006; 98:26-38.
12. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51.
13. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988; 48:7067-71.
14. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001; 3(suppl):30-5.
15. Kaufman PA, Paroly W, Rinaldi D, et al. Randomized double-blind phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with early stage and advanced breast cancer. Breast Cancer Res Treat 2004; 88(suppl):S59 (Abstract 1054).
16. Lokich JJ. Same day pegfilgrastim and CHOP chemotherapy for non-Hodgkin's lymphoma. Am J Clin Oncol 2006; 29:361-3.
17. Wolf M, Bentley M, Marlton P, et al. Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47:2344-50.
18. Saven A, Schwartzberg L, Kaywin P, et al. Randomized, double-blind, phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin's lymphoma patients. J Clin Oncol 2006; 24(18 suppl):439s (Abstract 7570).
19. Cardoso F, Ferreira Filho AF, Crown J, et al. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study. Anticancer Res 2001; 21:789-95.
20. Cooper BW, Radivoyevitch T, Overmoyer BA, et al. Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. Breast Cancer Res Treat 2006; 97:311-8.
21. Schwartz J, Domchek SM, Hwang WT, et al. Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/ cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Ann Oncol 2005; 16:247-52.
22. Lambert-Falls R, Modugno S. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast in a phase II study. Clin Breast Cancer 2007; 7:697-704.